2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T465,Between November 28, 2013, and July 22, 2019, a total of 1228 participants underwent randomization; 610 were assigned to the fish-oil group and 618 to the placebo group. During 3.5 years of follow-up, the rate of serious cardiovascular events was significantly lower in the fish-oil group than in the placebo group (0.31 vs. 0.61 per 1000 patient-days; hazard ratio, 0.57; 95% confidence interval [CI], 0.47 to 0.70; P<0.001). The rate of the extended primary end point that included noncardiac causes of death appeared to be lower in the fish-oil group than in the placebo group, with a hazard ratio of 0.77 (95% CI, 0.65 to 0.90). The hazard ratio for cardiac death was 0.55 (95% CI, 0.40 to 0.75); for fatal and nonfatal myocardial infarction, 0.56 (95% CI, 0.40 to 0.80); for peripheral vascular disease leading to amputation, 0.57 (95% CI, 0.38 to 0.86); for fatal and nonfatal stroke, 0.37 (95% CI, 0.18 to 0.76); and for a first cardiovascular event or death from any cause, 0.73 (95% CI, 0.61 to 0.87). Adherence to the trial regimen and the incidence of adverse events did not differ meaningfully between the groups.31:Ta05,Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may have cardiovascular benefits in the general population, but efficacy among patients receiving hemodialysis is uncertain. In a double-blind, randomized, placebo-controlled trial conducted at 26 sites in Canada and Australia, we assigned adult patients receiving maintenance hemodialysis to daily supplementation with fish oil (4 g of n-3 polyunsaturated fatty acids [1.6 g of EPA and 0.8 g of DHA]) or corn-oil placebo. The primary end point was a composite of all serious cardiovascular events including sudden and nonsudden cardiac death, fatal and nonfatal myocardial infarction, peripheral vascular disease leading to amputation, and fatal and nonfatal stroke. Secondary end points included extension of the primary end point to include noncardiac causes of death, the individual components of the primary end point, and a first cardiovascular event or death from any cause. Between November 28, 2013, and July 22, 2019, a total of 1228 participants underwent randomization; 610 were assigned to the fish-oil group and 618 to the placebo group. During 3.5 years of follow-up, the rate of serious cardiovascular events was significantly lower in the fish-oil group than in the placebo group (0.31 vs. 0.61 per 1000 patient-days; hazard ratio, 0.57; 95% confidence interval [CI], 0.47 to 0.70; P<0.001). The rate of the extended primary end point that included noncardiac causes of death appeared to be lower in the fish-oil group than in the placebo group, with a hazard ratio of 0.77 (95% CI, 0.65 to 0.90). The hazard ratio for cardiac death was 0.55 (95% CI, 0.40 to 0.75); for fatal and nonfatal myocardial infarction, 0.56 (95% CI, 0.40 to 0.80); for peripheral vascular disease leading to amputation, 0.57 (95% CI, 0.38 to 0.86); for fatal and nonfatal stroke, 0.37 (95% CI, 0.18 to 0.76); and for a first cardiovascular event or death from any cause, 0.73 (95% CI, 0.61 to 0.87). Adherence to the trial regimen and the incidence of adverse events did not differ meaningfully between the groups. The rate of serious cardiovascular events among participants receiving maintenance hemodialysis was lower with daily supplementation with n-3 fatty acids than with placebo. (Supported by the Heart and Stroke Foundation of Canada and others; PISCES ClinicalTrials.gov number, ISRCTN00691795.).32:T779,Omega-3 fatty acids (ω-3 FA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are essential nutrients known for their anti-inflammatory properties, which involve reducing pro-inflammatory cytokines, eicosanoids, and insulin-like growth factor-1. This suggests their potential to alleviate acne severity, especially when deficits are present. To elevate EPA/DHA levels in acne patients through dietary intervention and supplementation, observing subsequent clinical effects. Over 16 weeks, 60 patients without prescription medication (n = 23 acne comedonica [AC], n = 37 acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating oral algae-derived ω-3 FA supplementation (600 mg DHA/300 mg EPA week 1-8, 800 mg DHA/400 mg EPA week 8-16). At four visits (V1-V4), blood EPA/DHA levels were tracked using the HS-omega 3 index® (EPA/DHA (%) of total identified fatty acids in erythrocytes; target 8%-11%, deficit <8%, severe deficit <4%), alongside clinical assessments and standardized questionnaires. At baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS-omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non-inflammatory lesions were observed (p < 0.001). While self-reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported. Many acne patients have a ω-3 FA deficit. The HS-omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae-derived ω-3 FA. Acne severity improved significantly in patients with target ω-3 FA levels.33:T9f0,AbstractBackgroundOmega‐3 fatty acids (ω‐3 FA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are essential nutrients known for their anti‐inflammatory properties, which involve reducing pro‐inflammatory cytokines, eicosanoids, and insulin‐like growth factor‐1. This suggests their potential to alleviate acne severity, especially when deficits are present.AimsTo elevate EPA/DHA levels in acne patients through dietary intervention and supplementation, observing subsequent clinical effects.MethodsOver 16 weeks, 60 patients without prescription medication (n = 23 acne comedonica [AC], n = 37 acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating oral algae‐derived ω‐3 FA supplementation (600 mg DHA/300 mg EPA week 1–8, 800 mg DHA/400 mg EPA week 8–16). At four visits (V1–V4), blood EPA/DHA levels were tracked using the HS‐omega 3 index® (EPA/DHA (%) of total identified fatty acids in erythrocytes; target 8%–11%, deficit <8%, severe deficit <4%), alongside clinical assessments and standardized questionnaires.ResultsAt baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS‐omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non‐inflammatory lesions were observed (p < 0.001). While self‐reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported.ConclusionMany acne patients have a ω‐3 FA deficit. The HS‐omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae‐derived ω‐3 FA. Acne severity improved significantly in patients with target ω‐3 FA levels.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Omega-3 Fatty Acid: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Omega-3 Fatty Acid (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Omega-3%20Fatty%20Acid\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Omega-3 Fatty Acid\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Omega-3%20Fatty%20Acid\"}]}}"}}]],["$","$L2f",null,{"title":"Omega-3 Fatty Acid: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Omega-3 Fatty Acid — concise summaries and practical next steps.","papers":[{"doi":"10.1038/s41380-026-03759-1","pmid":"42680855","title":"Nutraceuticals and phytoceuticals for the treatment of major depressive disorder: a systematic review and network meta-analysis","journal_title":"Molecular Psychiatry","journal_issn":"1359-4184","published_at":"2026-09-01T00:00:00.000Z","url":"https://doi.org/10.1038/s41380-026-03759-1","source_score":12,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-06T06:22:58.221Z","updated_at":"2026-09-06T06:22:58.221Z","tags":[{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"brand","value":"WS5570","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"brand","value":"ZE117","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"condition","value":"Major Depressive Disorder","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"generic","value":"cholecalciferol","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"generic","value":"citicoline","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"generic","value":"curcumin","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"generic","value":"docosahexaenoic acid","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"generic","value":"eicosapentaenoic acid","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"generic","value":"fluoxetine","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"modality","value":"Herbal Extract","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"modality","value":"Nutraceutical","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"modality","value":"Omega-3 Fatty Acid","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"modality","value":"Phytoceutical","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"modality","value":"Vitamin Supplement","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"sample_size","value":"n=15757","value_numeric":15757},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"warning","value":"Age, sex, and MDD severity subgroup data were not consistently reported across included trials, limiting generalizability to specific patient populations.","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"warning","value":"Effect sizes for top-ranked agents (EPA, vitamin D3, ZE117) were explicitly flagged by authors as 'higher-than-expected/unrealistic,' even after quality filtering — clinicians should not interpret these SMDs at face value.","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"warning","value":"St. John's wort brand names (ZE117, WS5570) represent distinct extracts with potentially different pharmacological profiles; pooling across brands was not performed but both appear in the analysis.","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03759-1","tag_type":"warning","value":"The network includes 137 distinct compound combinations across 163 trials, making many node comparisons sparse and indirect; transitivity assumptions may not fully hold.","value_numeric":null}],"summaries":{"what_studied":"A systematic review and network meta-analysis of 163 RCTs (n = 15,757) evaluated nutraceuticals and phytoceuticals vs. placebo or antidepressants (TAU) for major depressive disorder (MDD), examining depressive symptoms, treatment response, remission, anxiety, tolerability, and acceptability.","key_result":"After restricting to high-quality evidence (≥2 RCTs, low risk of bias, non-sponsored, non-outlier), EPA (SMD = −1.67), vitamin D3 (SMD = −1.59), and St. John's wort extract ZE117 (SMD = −1.02) showed the largest effect sizes vs. placebo for depressive symptoms — but these effect sizes were deemed higher-than-expected or unrealistic. Curcumin showed a moderate benefit for anxiety (SMD = −0.58). Citicoline was linked to significantly more dropouts. Overall confidence in evidence was **low to very low**, and larger effect sizes correlated with lower study quality (meta-regression).","limitations":"- Substantial heterogeneity (I² = 85.3%) and significant global inconsistency limit pooled estimates.\n- Confidence in all evidence rated low to very low (CINeMA/AMSTAR-Plus).\n- Even filtered analyses produced effect sizes judged unrealistically large, suggesting residual bias.","practice_takeaway":"Clinicians should be cautious about recommending nutraceuticals or phytoceuticals for MDD — current evidence is low quality, and apparent large benefits (especially for EPA, vitamin D3, and St. John's wort) are likely inflated by poor study design. Rigorous, well-powered RCTs are needed before routine use can be supported."}},{"doi":"10.1016/j.jad.2026.122277","pmid":"42462928","title":"A randomized trial of omega-3 fatty acids plus inositol versus N-acetylcysteine for the treatment of depression and mania in emotionally dysregulated youth age 5–17 with and without autism traits","journal_title":"Journal of Affective Disorders","journal_issn":"0165-0327","published_at":"2026-07-16T00:00:00.000Z","url":"https://doi.org/10.1016/j.jad.2026.122277","source_score":12,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-26T13:44:38.609Z","updated_at":"2026-07-26T13:44:38.609Z","tags":[{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"age_group","value":"child","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"condition","value":"Autism Spectrum Disorder","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"condition","value":"Depression","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"condition","value":"Emotional Dysregulation","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"condition","value":"Mania","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"generic","value":"inositol","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"generic","value":"N-acetylcysteine","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"generic","value":"omega-3 fatty acids","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"modality","value":"Nutraceutical","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"modality","value":"Omega-3 Fatty Acid","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.jad.2026.122277","tag_type":"warning","value":"The trial was open-label, not double-blind, which substantially increases risk of bias in outcome assessment. Between-group comparisons were non-significant, and the abstract does not report the total sample size (N), limiting confidence in effect size estimates. The level of evidence is provisionally set to 2 given the RCT design, but the open-label methodology may warrant downgrading. 'Autism traits' were defined dimensionally by CBCL score rather than formal DSM diagnosis, so findings may not generalize to clinically diagnosed ASD populations.","value_numeric":null}],"summaries":{"what_studied":"This RCT compared omega-3 fatty acids plus inositol (O3I: 1020 mg EPA + 1000–2000 mg inositol) versus N-acetylcysteine (NAC: 1800–2700 mg/day) as open-label treatments over 6 weeks in children and adolescents aged 5–17 with emotional dysregulation, with or without autism traits (AT) defined by CBCL scores.","key_result":"Both O3I and NAC produced modest improvements in depression and mania with no significant between-group difference overall. O3I showed statistically significant within-group improvement in depression (CDI); NAC showed a greater (but non-significant) decrease in mania (P-YMRS). In youth with AT, NAC outperformed O3I for mania and produced significant within-group improvements on SRS and BRIEF scores.","limitations":"Open-label design introduces performance and detection bias. The 6-week duration is short for assessing sustained benefit. Sample size and power are not reported in the abstract, limiting interpretation of non-significant between-group comparisons.","practice_takeaway":"For emotionally dysregulated youth aged 5–17, both O3I and NAC appear modestly beneficial; clinicians may favor NAC when autism traits and mania are prominent. Neither treatment showed a clear superiority overall, so either may be a reasonable first-line nutraceutical option pending larger blinded trials."}},{"doi":"10.1038/s41433-026-04626-7","pmid":"42288617","title":"Identifying potential therapeutic targets for high myopia via a case-control study and Mendelian randomisation analyses of the human blood metabolome","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-06-13T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04626-7","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-18T13:24:20.404Z","updated_at":"2026-06-18T13:24:20.404Z","tags":[{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"condition","value":"High Myopia","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"generic","value":"docosahexaenoic acid","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"generic","value":"glutamine","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"generic","value":"isobutyrylcarnitine","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"generic","value":"tyrosine","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"modality","value":"Amino Acid Supplementation","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"modality","value":"Omega-3 Fatty Acid","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"sample_size","value":"n=50372","value_numeric":50372},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"study_design","value":"Mendelian Randomisation with Case-Control Validation","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"warning","value":"One editorial board member (AG) is on the journal's board, though authors state no competing interest conflict.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"warning","value":"Study design is labeled 'Mendelian Randomisation with Case-Control Validation' — the case-control component had a separate, unspecified sample size not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"warning","value":"The MR effect sizes are very close to 1.0 (e.g., OR 0.98–0.99), raising questions about clinical meaningfulness despite statistical significance.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04626-7","tag_type":"warning","value":"The UK Biobank GWAS used for high myopia outcomes is predominantly European ancestry, limiting generalisability to Asian populations where high myopia prevalence is highest.","value_numeric":null}],"summaries":{"what_studied":"This study used Mendelian randomisation (MR) of 122 blood metabolites (from 3 GWASs) against high myopia data from 50,372 UK Biobank participants, then validated findings in a real-world case-control study to identify causal metabolite biomarkers and drug targets for high myopia prevention.","key_result":"MR identified 5 metabolites linked to high myopia risk: glutamine (OR 0.98, 95% CI 0.97–1.00), tyrosine (OR 0.98, 95% CI 0.97–0.99), degree of unsaturation (OR 0.98, 95% CI 0.98–0.99), and DHA (OR 0.99, 95% CI 0.98–1.00) were protective, while isobutyrylcarnitine was a risk factor (OR 1.09, 95% CI 1.05–1.13). The case-control study confirmed lower glutamine (OR 0.76, 95% CI 0.58–0.98) and tyrosine (OR 0.72, 95% CI 0.55–0.94) levels associated with increased high myopia risk.","limitations":"- MR uses genetic proxies from largely European-ancestry GWAS data, limiting generalisability to other populations.\n- Effect sizes from MR are modest (ORs close to 1.0), and clinical magnitude of metabolite changes is unclear.\n- Only glutamine and tyrosine were validated in the case-control study; DHA, degree of unsaturation, and isobutyrylcarnitine lacked real-world validation.","practice_takeaway":"Glutamine, tyrosine, and DHA emerge as candidate protective targets against high myopia, warranting trials of dietary or supplemental interventions. Clinicians should watch for future mechanistic and interventional studies before recommending specific metabolite-based strategies."}},{"doi":"10.1056/nejmoa2513032","pmid":"41201837","title":"Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis","journal_title":"New England Journal of Medicine","journal_issn":"0028-4793","published_at":"2025-11-07T00:00:00.000Z","url":"https://doi.org/10.1056/nejmoa2513032","source_score":473,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-12","doi":"10.1056/nejmoa2513032","days":"7","issn":"0028-4793","rank":"6","field":"Clinical Medicine","score":"473","category":"Medicine, General & Internal","categories":["Medicine, General & Internal"],"_categories":["Medicine, General & Internal"]},"pubmed":{"doi":"10.1056/NEJMoa2513032","title":"Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.","journal":"The New England journal of medicine","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41201837","conclusions":"","publication_date":"2025-11-07T00:00:00"},"crossref":{"DOI":"10.1056/nejmoa2513032","URL":"https://doi.org/10.1056/nejmoa2513032","ISSN":["0028-4793","1533-4406"],"link":[{"URL":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa2513032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"128-137","type":"journal-article","issue":"2","score":1,"title":["Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis"],"author":[{"given":"Charmaine E.","family":"Lok","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Health Network, Toronto"},{"name":"Faculty of Medicine, University of Toronto, Toronto"},{"name":"Toronto General Hospital Research Institute, Toronto"}]},{"given":"Michael","family":"Farkouh","sequence":"additional","affiliation":[{"name":"Smidt Heart Institute, Cedars Health System, Los Angeles"},{"name":"Peter Munk Cardiac Centre, University Health Network, Toronto"}]},{"given":"Brenda R.","family":"Hemmelgarn","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Alberta, Edmonton, Canada"}]},{"given":"Louise M.","family":"Moist","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistry, London, ON, Canada"}]},{"given":"Kevan R.","family":"Polkinghorne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Monash University and Monash Health, Clayton, VIC, Australia"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, Toronto"}]},{"given":"Paul","family":"Tam","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Scarborough Health Network, Toronto"}]},{"given":"Marcello","family":"Tonelli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Calgary, Calgary, AB, Canada"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto"},{"name":"Peter Munk Cardiac Centre, University Health Network, Toronto"},{"name":"Women’s College Hospital, Toronto"}]}],"funder":[{"id":[{"id":"10.13039/100004411","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100004411","name":"Heart and Stroke Foundation of Canada","award":["G-15- 0009388"],"award-info":[{"award-number":["G-15- 0009388"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100004411","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100004411","name":"Heart and Stroke Foundation of Canada","award":["Ontario Chapter, personnel award #7511-A"],"award-info":[{"award-number":["Ontario Chapter, personnel award #7511-A"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100008958","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100008958","name":"Lawson Health Research Institute","doi-asserted-by":"publisher"},{"name":"Kidney CARE Network International"},{"id":[{"id":"10.13039/501100000925","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100000925","name":"National Health and Medical Research Council","award":["APP1123392"],"award-info":[{"award-number":["APP1123392"]}],"doi-asserted-by":"publisher"},{"name":"Peter Munk Cardiac Care Innovation Fund","award":["CMT-1516-237"],"award-info":[{"award-number":["CMT-1516-237"]}]}],"issued":{"date-parts":[[2026,1,8]]},"member":"150","prefix":"10.1056","source":"Crossref","volume":"394","created":{"date-time":"2025-11-07T16:30:51Z","timestamp":1762533051000,"date-parts":[[2025,11,7]]},"indexed":{"date-time":"2026-01-08T04:23:09Z","timestamp":1767846189874,"date-parts":[[2026,1,8]]},"license":[{"URL":"http://www.nejmgroup.org/legal/terms-of-use.htm","start":{"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000,"date-parts":[[2026,1,8]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"http://www.nejm.org/doi/10.1056/NEJMoa2513032"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T22:00:26Z","timestamp":1767823226000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"0028-4793"},{"type":"electronic","value":"1533-4406"}],"published":{"date-parts":[[2026,1,8]]},"publisher":"Massachusetts Medical Society","reference":[{"DOI":"10.1016/j.kint.2019.07.012","key":"e_1_3_5_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41581-022-00542-7","key":"e_1_3_5_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ekir.2024.05.014","key":"e_1_3_5_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1053/ajkd.1998.v32.pm9820470","key":"e_1_3_5_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.mcna.2004.11.003","key":"e_1_3_5_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.31083/j.rcm2407185","key":"e_1_3_5_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s43016-021-00289-7","key":"e_1_3_5_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14235146","key":"e_1_3_5_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_5_10_2","year":"2024","issue":null,"author":"Dinu M","volume":"31","first-page":"1863","unstructured":"Dinu M, Sofi F, Lotti S, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol 2024;31:1863-1875.38869144","article-title":"Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis.","journal-title":"Eur J Prev Cardiol","doi-asserted-by":null},{"DOI":"10.1186/s12937-024-01051-y","key":"e_1_3_5_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu16111610","key":"e_1_3_5_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10408398.2022.2056867","key":"e_1_3_5_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000343741","key":"e_1_3_5_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1053/j.jrn.2010.06.020","key":"e_1_3_5_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clnu.2019.02.041","key":"e_1_3_5_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjopen-2023-072239","key":"e_1_3_5_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/science.aao5610","key":"e_1_3_5_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_5_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing 2025 (https://www.r-project.org/).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1053/j.jrn.2025.02.001","key":"e_1_3_5_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/ki.2013.4","key":"e_1_3_5_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1053/ajkd.2002.32775","key":"e_1_3_5_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2169/internalmedicine.54.4931","key":"e_1_3_5_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2012.3473","key":"e_1_3_5_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu12123782","key":"e_1_3_5_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jacc.2011.06.063","key":"e_1_3_5_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1812792","key":"e_1_3_5_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2020.22258","key":"e_1_3_5_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fcvm.2021.802306","key":"e_1_3_5_29_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/eurheartj/suaa115","key":"e_1_3_5_30_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/heartjnl-2020-316780","key":"e_1_3_5_31_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.121.055560","key":"e_1_3_5_32_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/JAHA.122.029109","key":"e_1_3_5_33_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12944-024-02246-2","key":"e_1_3_5_34_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.121.054539","key":"e_1_3_5_35_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/01.CIR.0000069566.78305.33","key":"e_1_3_5_36_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/JAHA.121.021431","key":"e_1_3_5_37_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCOUTCOMES.118.004584","key":"e_1_3_5_38_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0735-1097(18)32326-X","key":"e_1_3_5_39_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.0427","key":"e_1_3_5_40_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,8]]}},"alternative-id":["10.1056/NEJMoa2513032"],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["New England Journal of Medicine"],"published-print":{"date-parts":[[2026,1,8]]},"reference-count":39,"published-online":null,"references-count":39,"short-container-title":["N Engl J Med"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1056/nejmoa2513032","is_oa":false,"title":"Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis","updated":"2025-11-08T00:30:58+00:00","published_date":"2025-11-07","best_oa_location":null}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1056/nejmoa2513032","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"condition","value":"End-Stage Kidney Disease","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"generic","value":"docosahexaenoic acid","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"generic","value":"eicosapentaenoic acid","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"modality","value":"Omega-3 Fatty Acid","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"sample_size","value":"n=1228","value_numeric":1228},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"warning","value":"Adverse events were described as not meaningfully different, but specific rates were not given.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2513032","tag_type":"warning","value":"Only abstract-level data were provided; absolute event counts were not reported.","value_numeric":null}],"summaries":{"what_studied":"A double-blind, randomized, placebo-controlled trial at 26 sites in Canada and Australia assigned 1228 adults on maintenance hemodialysis to daily fish oil (4 g n-3 PUFA: 1.6 g EPA, 0.8 g DHA) or corn-oil placebo for 3.5 years; the primary outcome was a composite of serious cardiovascular events.","key_result":"The primary event rate was 0.31 vs 0.61 per 1000 patient-days (hazard ratio, 0.57; 95% CI, 0.47–0.70; P<0.001). Secondary results favored fish oil, including cardiac death (HR, 0.55; 95% CI, 0.40–0.75) and first cardiovascular event or death from any cause (HR, 0.73; 95% CI, 0.61–0.87); adherence and adverse events were similar between groups.","practice_takeaway":"In adults receiving maintenance hemodialysis, daily n-3 fatty acids reduced serious cardiovascular events over 3.5 years versus placebo without more adverse events. This supports considering EPA/DHA supplementation to lower cardiovascular risk in this population."}},{"doi":"10.1111/jocd.16434","pmid":"38982829","title":"Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2024-07-10T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.16434","source_score":495,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-07-15","doi":"10.1111/jocd.16434","days":"30","issn":"1473-2130","rank":"1","field":"Clinical Medicine","score":"495","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.16434","title":"Exploring the potential of omega-3 fatty acids in acne patients: A prospective intervention study.","journal":"Journal of cosmetic dermatology","methods":"","results":"At baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS-omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non-inflammatory lesions were observed (p < 0.001). While self-reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported.","abstract":"$32","keywords":["Mediterranean diet","exposome factors","nutraceuticals","nutrition","supplementation"],"pubmed_id":"38982829","conclusions":"Many acne patients have a ω-3 FA deficit. The HS-omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae-derived ω-3 FA. Acne severity improved significantly in patients with target ω-3 FA levels.","publication_date":"2024-07-10T00:00:00"},"crossref":{"DOI":"10.1111/jocd.16434","URL":"https://doi.org/10.1111/jocd.16434","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.16434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"3295-3304","type":"journal-article","issue":"10","score":1,"title":["Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study"],"author":[{"given":"Anne","family":"Guertler","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Katharina","family":"Neu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Diana","family":"Lill","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Benjamin","family":"Clanner‐Engelshofen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"},{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine University of Miami Coral Gables USA"}]},{"given":"Markus","family":"Reinholz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital LMU Munich Munich Germany"}]}],"issued":{"date-parts":[[2024,7,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"23","archive":["Portico"],"created":{"date-time":"2024-07-10T07:02:43Z","timestamp":1720594963000,"date-parts":[[2024,7,10]]},"indexed":{"date-time":"2025-08-27T15:44:45Z","timestamp":1756309485562,"date-parts":[[2025,8,27]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000,"date-parts":[[2024,7,10]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.16434"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2024-03-26"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2024-06-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2024-07-10"}],"deposited":{"date-time":"2024-09-27T01:16:14Z","timestamp":1727399774000,"date-parts":[[2024,9,27]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2024,7,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/ced.14239","key":"e_1_2_12_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clindermatol.2022.04.001","key":"e_1_2_12_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2022.4306","key":"e_1_2_12_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16614","key":"e_1_2_12_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14820","key":"e_1_2_12_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21739","key":"e_1_2_12_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.15726","key":"e_1_2_12_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-020-00542-y","key":"e_1_2_12_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/exd.12898","key":"e_1_2_12_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S69135","key":"e_1_2_12_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.15862","key":"e_1_2_12_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-1802","key":"e_1_2_12_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.14779","key":"e_1_2_12_14_1","year":"2022","issue":null,"author":"Guertler A","volume":"20","first-page":"1023","unstructured":null,"article-title":"Clinical effects of omega‐3 fatty acids on acne vulgaris","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"crossref"},{"DOI":"10.3390/nu12040898","key":"e_1_2_12_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_12_16_1","year":"2023","issue":null,"author":"Krupa K","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3390/nu8030128","key":"e_1_2_12_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms22136965","key":"e_1_2_12_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/openhrt-2015-000385","key":"e_1_2_12_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000492116","key":"e_1_2_12_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.14683","key":"e_1_2_12_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu10111662","key":"e_1_2_12_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5021/ad.2017.29.1.20","key":"e_1_2_12_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1359/jbmr.1999.14.7.1153","key":"e_1_2_12_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.1300298","key":"e_1_2_12_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms21030741","key":"e_1_2_12_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbrc.2008.01.062","key":"e_1_2_12_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2013.505","key":"e_1_2_12_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.immuni.2013.05.015","key":"e_1_2_12_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14374","key":"e_1_2_12_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1476-511X-7-36","key":"e_1_2_12_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1476-511X-11-165","key":"e_1_2_12_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_12_33_1","year":"2019","issue":null,"author":"Schacky C","volume":"60","first-page":"1319","unstructured":null,"article-title":"Confusion about the effects of omega‐3 fatty acids: contemplation of study data taking the omega‐3 index into consideration","journal-title":"Internist (Berl)","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_12_34_1","year":"2021","issue":null,"author":"Zainab Z","volume":"33","first-page":"60","unstructured":null,"article-title":"Effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.3390/nu7115459","key":"e_1_2_12_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2903/j.efsa.2021.6344","key":"e_1_2_12_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ypmed.2004.02.030","key":"e_1_2_12_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1017/S0029665120006989","key":"e_1_2_12_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1610-0387.2010.07466.x","key":"e_1_2_12_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ics.12258","key":"e_1_2_12_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/1475-2891-9-36","key":"e_1_2_12_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1017/S0007114516000544","key":"e_1_2_12_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"e_1_2_12_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu9090930","key":"e_1_2_12_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13776","key":"e_1_2_12_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.12788/cutis.0273","key":"e_1_2_12_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00680-z","key":"e_1_2_12_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.atherosclerosis.2015.03.043","key":"e_1_2_12_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4236/wjcd.2012.21003","key":"e_1_2_12_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jcmm.17546","key":"e_1_2_12_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.plefa.2017.01.009","key":"e_1_2_12_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.14475","key":"e_1_2_12_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5826/dpc.0602a05","key":"e_1_2_12_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14245293","key":"e_1_2_12_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.16434"],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,10]]},"reference-count":53,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2024,7,10]]},"references-count":53,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":5},"unpaywall":{"doi":"10.1111/jocd.16434","is_oa":true,"title":"Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study","updated":"2025-09-06T02:51:56+00:00","published_date":"2024-07-10","best_oa_location":{"url":"https://doi.org/10.1111/jocd.16434","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jocd.16434"}}},"created_at":"2025-09-20T07:38:03.516Z","updated_at":"2025-09-20T07:53:53.397Z","tags":[{"paper_doi":"10.1111/jocd.16434","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"modality","value":"Omega-3 Fatty Acid","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"sample_size","value":"n=60","value_numeric":60},{"paper_doi":"10.1111/jocd.16434","tag_type":"study_design","value":"Single-Arm Interventional Study","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"warning","value":"Clinical improvements were reported without absolute lesion count or QoL changes.","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"warning","value":"Diet and supplementation were combined, and dairy intake fell, so effects of omega‑3 alone are unclear.","value_numeric":null},{"paper_doi":"10.1111/jocd.16434","tag_type":"warning","value":"No comparator arm; study design classification is approximate.","value_numeric":null}],"summaries":{"what_studied":"A 16-week prospective, single-arm study in 60 acne patients not on prescription medication tested a Mediterranean diet plus algae-derived omega-3 supplementation (weeks 1–8: 600 mg DHA/300 mg EPA; weeks 8–16: 800 mg DHA/400 mg EPA), tracking HS‑Omega‑3 Index and clinical acne measures at four visits.","key_result":"At baseline, 98.3% had an EPA/DHA deficit; the mean HS‑Omega‑3 Index increased from 4.9% at V1 to 8.3% at V4 (p<0.001), with higher indices in comedonal than papulopustular acne at V4 (p=0.035). Objective improvements in inflammatory and non‑inflammatory lesions (p<0.001) and quality of life (p<0.001) were observed; dairy intake decreased (p<0.001), compliance was good, and no adverse events were reported.","limitations":"No control group and the combined intervention (diet plus supplementation with reduced dairy) prevent attributing effects to omega‑3 alone. The report provides p‑values without absolute changes in lesion counts or quality‑of‑life scores.","practice_takeaway":"Raising the HS‑Omega‑3 Index via a Mediterranean diet plus algae‑derived DHA/EPA to around 8% over 16 weeks was associated with improved acne severity and quality of life, with no reported harms; interpret as preliminary due to the uncontrolled design."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Omega-3 Fatty Acid"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Omega-3 Fatty Acid"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Omega-3 Fatty Acid"}}}]]

Papers